OncoMatch/Clinical Trials/NCT06157151
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Is NCT06157151 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including PRGN-2009 plus Pembrolizumab and Pembrolizumab alone for cervical cancer.
Treatment: PRGN-2009 plus Pembrolizumab · Pembrolizumab alone — This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) positive (positive)
Tumors are confirmed positive for PD-L1
Required: HPV16 positive (positive)
Tumors are confirmed positive for ... HPV16/18
Required: HPV18 positive (positive)
Tumors are confirmed positive for ... HPV16/18
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-pd-1 therapy (pembrolizumab) — recurrent or metastatic
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Must have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- National Institute of Health · Bethesda, Maryland
- University of Washington · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06157151 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anti-pd-1 therapy.
Does this trial require CD274?
Yes, CD274 positive is a required biomarker for enrollment.
Does this trial require HPV16?
Yes, HPV16 positive is a required biomarker for enrollment.
Does this trial require HPV18?
Yes, HPV18 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages